A role for glia in the progression of Rett’s syndrome
Open Access
- 29 June 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature
- Vol. 475 (7357), 497-500
- https://doi.org/10.1038/nature10214
Abstract
Rett's syndrome, a disorder caused by loss of function of methyl CpG-binding protein 2 (MeCP2), is associated with various neurological symptoms on the autism spectrum. Although impaired neurons are the underlying cause of nervous system failure in Rett's syndrome, experiments in a mouse model show that the genetic correction of MeCP2 expression in glial cells — principally in astrocytes — can reverse three hallmark behaviour abnormalities of the neurological disorder. Neuronal morphology and neurotransmitter markers are also rescued, suggesting an interactive mechanism between glial and neuronal cells in Rett's syndrome initiation and progression. Rett’s syndrome (RTT) is an X-chromosome-linked autism spectrum disorder caused by loss of function of the transcription factor methyl-CpG-binding protein 2 (MeCP2)1. Although MeCP2 is expressed in most tissues2, loss of MeCP2 expression results primarily in neurological symptoms1,3,4. Earlier studies suggested the idea that RTT is due exclusively to loss of MeCP2 function in neurons2,4,5,6,7,8,9,10. Although defective neurons clearly underlie the aberrant behaviours, we and others showed recently that the loss of MECP2 from glia negatively influences neurons in a non-cell-autonomous fashion11,12,13. Here we show that in globally MeCP2-deficient mice, re-expression of Mecp2 preferentially in astrocytes significantly improved locomotion and anxiety levels, restored respiratory abnormalities to a normal pattern, and greatly prolonged lifespan compared to globally null mice. Furthermore, restoration of MeCP2 in the mutant astrocytes exerted a non-cell-autonomous positive effect on mutant neurons in vivo, restoring normal dendritic morphology and increasing levels of the excitatory glutamate transporter VGLUT1. Our study shows that glia, like neurons, are integral components of the neuropathology of RTT, and supports the targeting of glia as a strategy for improving the associated symptoms.Keywords
This publication has 30 references indexed in Scilit:
- A Model for Neural Development and Treatment of Rett Syndrome Using Human Induced Pluripotent Stem CellsCell, 2010
- Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypesNature, 2010
- Loss of MeCP2 in aminergic neurons causes cell-autonomous defects in neurotransmitter synthesis and specific behavioral abnormalitiesProceedings of the National Academy of Sciences of the United States of America, 2009
- Non–cell autonomous toxicity in neurodegenerative disorders: ALS and beyondThe Journal of cell biology, 2009
- Non–cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphologyNature Neuroscience, 2009
- Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytesNature Biotechnology, 2008
- Deletion of Mecp2 in Sim1-Expressing Neurons Reveals a Critical Role for MeCP2 in Feeding Behavior, Aggression, and the Response to StressNeuron, 2008
- Inducible Cre recombinase activity in mouse mature astrocytes and adult neural precursor cellsTransgenic Research, 2008
- MeCP2 Controls Excitatory Synaptic Strength by Regulating Glutamatergic Synapse NumberNeuron, 2007
- Enhanced anxiety and stress-induced corticosterone release are associated with increased Crh expression in a mouse model of Rett syndromeProceedings of the National Academy of Sciences of the United States of America, 2006